Compounds / PT-141

PT-141

Also known as: Bremelanotide, Vyleesi (brand)

Established human clinical FDA-approved (brand product) Category: Melanocortin

The compounds described in this library are research-use-labeled chemicals and are not FDA-approved for human use. This content is factual scientific reference drawn from published literature. It is not medical, dosing, or purchasing advice. VialReport does not sell, supply, or distribute any compound.

Short summary

A melanocortin receptor agonist approved by the FDA under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. It came from the same research program as Melanotan II but has a different profile and a genuine approval.

Dive deeper

Origin and Development

Developed as a metabolite-derived analogue arising from work on Melanotan II, after observations of effects unrelated to pigmentation. Developed as bremelanotide by Palatin Technologies and approved by the FDA in 2019.

Mechanism as Understood in the Literature

Bremelanotide activates multiple melanocortin receptor subtypes and is described in the approved labeling as a nonselective melanocortin receptor agonist. Although MC4R signaling is considered relevant, the mechanism by which the approved product improves the condition it treats is not established. The approved labeling carries a warning about focal hyperpigmentation, which may not resolve in all cases, so it should not be described as free of pigmentary effects.

Research Status

Well characterized. Approval was supported by randomized placebo-controlled trials (the RECONNECT studies) in premenopausal women with hypoactive sexual desire disorder.

Regulatory status · approved

FDA-approved as a prescription medicine under several brand names.

Approved indications and formulations differ by brand.

Material sold outside the approved supply chain is not the approved product, regardless of how it is labeled.

Commonly Confused With

Frequently discussed alongside Melanotan II and sometimes sold interchangeably with it. They are different molecules with different receptor activity profiles, and PT-141 is approved while Melanotan II is not. Both act at melanocortin receptors and neither should be described as free of pigmentary effects.

How This Compound Is Marketed

Vendors in this market commonly market this compound for libido and sexual function, generally without reference to the narrow approved indication. These are vendors’ marketing claims, not VialReport’s. VialReport does not verify, evaluate, or endorse them, and nothing on this page is medical, dosing, or purchasing advice or a recommendation to use any compound. See “Research status” above for what the published literature actually establishes.

Vendor marketing generally makes no reference to the narrow approved indication described above.

Analytical Profile

A cyclic heptapeptide, molecular weight approximately 1025 Da for the free base; bremelanotide acetate differs, and the form should be specified whenever mass or content is reported. Very close in mass to Melanotan II, which makes the two genuinely difficult to distinguish without a proper reference standard and an appropriate method. Given that they are sold in the same channels and sometimes confused, this is a compound where identity confirmation matters more than usual.

Stability and Handling

The approved product has defined manufacturer storage requirements.

Key Literature

  1. 01 Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.
  2. 02 Clayton AH, et al. Bremelanotide for female sexual dysfunctions in premenopausal women. Womens Health (Lond). 2016;12(3):325-337.

VialReport publishes factual reference information and independent test data. Nothing here is medical, dosing, or purchasing advice.

Published reports

Reports for PT-141

No reports for this compound yet.

Want a vendor’s version of this compound tested? Request it and we’ll notify you when a report publishes.

Request a test

Stay current

Get notified when new reports publish.

Free. We email when results are in, and nothing else.

Powered by MailerLite. No spam. Unsubscribe anytime.